Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge ABCHIX:GETIBS 73 ROA % is 5.83% as of Jun. 2026, which is 77% above its 10-year median of 3.29. GuruFocus rates CHIX:GETIBS with a GF Score™ of 73/100 and a GF Value™ of kr192.70 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Getinge AB ranks better than 68.5% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Getinge AB's annualizedNet Income for the quarter that ended in Jun. 2026 was kr3,364 Mil.
Getinge AB's average Total Assets over the quarter that ended in Jun. 2026 was kr57,693 Mil. Therefore, Getinge AB's annualized ROA % for the quarter that ended in Jun. 2026 was 5.83%.
The historical rank and industry rank for Getinge AB's ROA % or its related term are showing as below:
CHIX:GETIBs'
s ROA % Range Over the Past 10 Years
Min: -2.26 Med: 3.29 Max: 7.22
Current: 4.69
During the past 13 years, Getinge AB's highest ROA % was 7.22%. The lowest was -2.26%. And the median was 3.29%.
CHIX:GETIBs's ROA % is ranked better than 68.5% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs CHIX:GETIBs: 4.69
Getinge AB (CHIX:GETIBs) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Getinge AB ROA % Related Terms
Getinge AB ROA % Historical Data
* Premium members only.
The historical data trend for Getinge AB's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Getinge AB's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getinge AB ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getinge AB's ROA % distribution charts can be found below:
* The bar in red indicates where Getinge AB's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Getinge AB (CHIX:GETIBS) has a ROA % of 5.83% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Getinge AB and its competitors. This is 77% above median its historical median of 3.29. According to the industry distribution chart, Getinge AB ranks #269 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 31.5%.
Is Getinge AB's ROA % too high?
Getinge AB's current ROA % of 5.83% is 77% above median its 10-year median of 3.29. The Medical Devices & Instruments industry median ROA % is 0.65. Getinge AB's value of 5.83% is 803.9% above this industry median. Based on the distribution chart, Getinge AB ranks #269 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Getinge AB has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getinge AB ranks #269 out of 854 companies for ROA %. This puts Getinge AB in the upper half of its industry. The industry median ROA % is 0.65. Getinge AB's value of 5.83% is 803.9% above this benchmark. While the company's 10-year median is 3.29 vs. the industry median of 0.65, Getinge AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.65, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getinge AB's current ROA % of 5.83% is 803.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Getinge AB and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getinge AB's current ROA % is 5.83%, which is 77% above median its own 10-year median of 3.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (CHIX:GETIBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr192.70, compared to a current price of kr231.00 — trading 19.9% above its estimated fair value. The current ROA % is 5.83%, which is 77% above median its 10-year median of 3.29 and 803.9% above the Medical Devices & Instruments industry median of 0.65. Getinge AB's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Getinge AB (CHIX:GETIBS), the current ROA % is 5.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (CHIX:GETIBS) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of kr231.00 is trading 19.9% above its estimated GF Value™ of kr192.70.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for CHIX:GETIBS:
ROA %: 5.83% (77% above median its 10-year median of 3.29)
GF Value™: kr192.70 vs. price of kr231.00 (19.9% above fair value)
Industry Position: 803.9% above the Medical Devices & Instruments median (#269 of 854)
No single metric tells the full story. See the CHIX:GETIBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
73GF Score
Get the complete analysis for CHIX:GETIBS
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GETIBS has been successfully added to your 
